The Retatrutide Dose Schedule Used in Phase 2 Trials

Trust signals

> Reviewed by FormBlends Medical Team · Last updated May 2026 · 12 sources cited · Author: FormBlends Editorial

Key Takeaways

• The phase 2 retatrutide trial (Jastreboff et al., NEJM 2023) used a uniform 2 mg starting dose with 4-week titration steps to 4, 8, or 12 mg target doses
• The schedule was designed around the drug's triple-agonist pharmacology, which produces dose-dependent GI effects
• Mean 48-week weight loss ranged from 8.7% at 1 mg to 24.2% at 12 mg
• Retatrutide remains investigational; phase 3 (TRIUMPH program) is ongoing, and there is no FDA-approved dosing schedule
• FormBlends does not sell or supply retatrutide. This page summarizes published research, not a prescription protocol. Discuss with a licensed clinician.

Direct answer

In the phase 2 trial, retatrutide was started at 2 mg once weekly and escalated every 4 weeks. The 4 mg arm reached target after one step. The 8 mg arm reached target after two steps. The 12 mg arm reached target after three steps. A separate 1 mg arm stayed at 1 mg throughout. Target doses were maintained for the remainder of the 48-week study. This is the schedule that produced the published efficacy numbers, not a recommendation for individual use.

Table of contents

1. The exact phase 2 schedule, week by week
2. Why the schedule starts at 2 mg
3. The four-week step rationale
4. Dose-response: what each target produced
5. How tolerability shaped the schedule
6. Where the schedule could break down in real practice
7. The phase 3 (TRIUMPH) schedule and what is changing
8. What compounders actually reference
9. Contrary view: is a slower schedule better?
10. Decision framework
11. FAQ
12. Sources

The exact phase 2 schedule, week by week

Jastreboff and colleagues randomized 338 adults with obesity to placebo, 1 mg, 4 mg, 8 mg, or 12 mg target retatrutide. The 8 mg arm was further split into two initial-dose groups (2 mg and 4 mg). The protocol used the same starting dose across the escalating arms and stepped up at four-week intervals.

Target	Weeks 1-4	Weeks 5-8	Weeks 9-12	Weeks 13-16	Weeks 17-48
1 mg	1 mg	1 mg	1 mg	1 mg	1 mg
4 mg	2 mg	4 mg	4 mg	4 mg	4 mg
8 mg (2 mg initial)	2 mg	4 mg	8 mg	8 mg	8 mg
8 mg (4 mg initial)	4 mg	8 mg	8 mg	8 mg	8 mg
12 mg	2 mg	4 mg	8 mg	12 mg	12 mg

Dose was delivered once weekly by subcutaneous injection. Injection day was kept consistent across the study window. The trial allowed delaying an escalation step if the investigator judged a participant had not adapted to the current dose.

Why the schedule starts at 2 mg

The 2 mg starting dose was selected based on phase 1 single- and multiple-ascending-dose work. Phase 1 found that doses above roughly 2 mg without titration produced clinically meaningful nausea and vomiting in a substantial fraction of participants. Starting at 2 mg balanced two needs: enough drug to begin producing weight effects within the first month, but not so much that GI tolerance would derail the trial.

The 4 mg initial-dose subgroup in the 8 mg arm was included to test whether a faster-on-ramp tolerated equivalent outcomes. The published data showed comparable efficacy with somewhat higher early discontinuation in the 4 mg initial group.

The four-week step rationale

Retatrutide reaches steady state in roughly five to six weeks based on its half-life and elimination kinetics. Four-week steps approximate the time needed for plasma concentrations to stabilize at a given dose before adding another increment. This mirrors how semaglutide and tirzepatide titration schedules were originally designed.

Three biological windows were considered when setting the step length:

• Plasma steady state at the new dose (about 4-6 weeks)
• Adaptive change in gastric emptying rate (typically 2-4 weeks)
• Subjective tolerance for nausea and early satiety (highly variable, often 1-3 weeks)

Four weeks was the shortest interval that satisfied all three. A shorter step risks stacking an unstable plasma concentration on top of unresolved GI symptoms.

Dose-response: what each target produced

The 48-week efficacy data, reported as mean percentage change in body weight from baseline:

Dose	Mean weight loss	Approximate body weight change for a 220 lb baseline
Placebo	~2.1%	~5 lb
1 mg	~8.7%	~19 lb
4 mg	~17.1%	~38 lb
8 mg	~22.8%	~50 lb
12 mg	~24.2%	~53 lb

Two patterns stand out. First, the curve is steep between 1 mg and 4 mg, where doubling the dose nearly doubles the response. Second, the curve flattens between 8 mg and 12 mg, where a 50% dose increase yields about 1.4 additional percentage points of weight loss. The marginal benefit at the top of the range is real but small.

How tolerability shaped the schedule

The most common adverse events in the trial were nausea, diarrhea, vomiting, and constipation. The vast majority were mild or moderate. GI events clustered around the first four weeks of any new dose, which is the strongest practical argument for keeping the four-week step structure intact.

Discontinuation due to adverse events ran higher at 12 mg than at lower targets. The published rate at 12 mg was approximately 16% by week 48, versus roughly 6% in the placebo arm. The schedule was designed to keep this tolerable but did not eliminate it.

Where the schedule could break down in real practice

Outside a trial setting, three things are different.

Participants in the trial had close clinical contact, structured monitoring, and the ability to delay escalation. They also knew exactly what dose they were taking because the pharmacy prepared their syringes. None of those conditions apply automatically to off-label or compounded use.

Dose accuracy matters here. Phase 2 used a precise drug-device pairing. Reconstituted compounded preparations vary in concentration and require accurate measurement to hit any target on the schedule. Two milligrams in the trial is not necessarily two milligrams in a non-trial setting, depending on how preparation is handled. This is a pharmacy and clinician question, not a patient one.

The phase 3 (TRIUMPH) schedule and what is changing

The TRIUMPH program, Eli Lilly's phase 3 trial set, began in 2023 and continues through 2026-2027. Reported design elements include:

• Target doses generally in the 4-12 mg range, with cardiovascular-outcome and obesity sub-studies
• Longer treatment durations (up to 88 weeks in some arms)
• Maintenance and dose-reduction sub-studies designed to test what happens after sustained weight loss
• A diabetes-specific program (TRIUMPH-2) testing retatrutide for type 2 diabetes management

The phase 3 dosing builds on the phase 2 schedule rather than replacing it. Public readouts to date describe similar titration logic.

What compounders actually reference

503A compounding pharmacies preparing retatrutide for research clinicians cannot follow an FDA-approved schedule because none exists. The closest published reference is the phase 2 protocol. Whether a particular clinician matches it depends on their judgment and the patient's tolerance.

Retatrutide compounding sits in a different legal posture than compounded semaglutide or tirzepatide. There is no FDA-approved branded version of retatrutide for any indication, which means compounding does not have the "shortage of an approved drug" predicate that FDA has used for the GLP-1s. Whatever clinical use exists is investigational and not on a typical commercial telehealth platform.

FormBlends does not sell or supply retatrutide. This article is educational.

Contrary view: is a slower schedule better?

An argument can be made that the trial schedule was tuned for trial completion, not for individual tolerability. A real-world clinician might prefer 6 or 8 weeks per step to reduce the proportion of patients who give up due to nausea. The trade-off is a longer ramp-up to target dose, which delays the weight-loss benefit.

Conversely, some compounders and research clinicians have argued for faster schedules in lean, healthy individuals tolerating early doses well. This has not been studied. There is no published evidence that compressed schedules produce equivalent efficacy without worse side effects.

The honest position: the four-week step is the only schedule with published efficacy data behind it. Deviations are reasonable in some cases but should be made by a licensed clinician with the patient in front of them, not derived from forum advice.

Decision framework

If you are a patient curious about retatrutide: retatrutide is not available through FDA-approved channels. There is no consumer-facing access pathway that matches the trial. Phase 3 is ongoing. The most evidence-supported choice for weight loss today remains FDA-approved semaglutide or tirzepatide.

If you are a clinician evaluating the schedule: the Jastreboff phase 2 paper is the primary reference. The TRIUMPH program publications will refine it. Local enrollment in a phase 3 site is the safest path for a patient interested in retatrutide specifically.

If you are comparing GLP-1 schedules: retatrutide titration looks similar in pattern to tirzepatide but at higher absolute doses and with a steeper ceiling. The dosing math is not interchangeable between drugs.

Discuss with a licensed clinician.

FAQ

What is the retatrutide dose schedule from the phase 2 trial? Participants started at 2 mg once weekly and escalated every 4 weeks. The 4 mg target reached after one step, 8 mg after two steps, 12 mg after three steps. Target doses were held to week 48.

Why does retatrutide require dose escalation? The triple-agonist activity produces dose-dependent gastrointestinal effects. Stepping up gradually lets receptor signaling and gastric emptying adapt before the next increment.

How long was each titration step? Four weeks. Investigators could extend a step if symptoms had not resolved.

Did everyone reach 12 mg? No. Discontinuation rates were higher at 12 mg than at lower targets, and some participants held at lower doses.

Is the trial schedule the same as a prescription schedule? No. Retatrutide is not FDA-approved. There is no prescription schedule. Published research is informational.

What dose produces the best weight loss? At 48 weeks, 12 mg produced the highest mean loss (~24.2%), but the curve flattened between 8 mg and 12 mg.

Can the schedule be compressed? Not in any published study. Faster escalation likely worsens GI tolerability without a documented efficacy gain.

What happens after week 48? Phase 2 ended at week 48. Phase 3 (TRIUMPH) is testing longer durations, maintenance phases, and dose-reduction sub-studies.

Related guides

• Retatrutide Starting Dose: Why Phase 2 Began at 2 mg
• Retatrutide Once Weekly Dosing Schedule
• Retatrutide Titration Schedule How to Start
• Is Retatrutide Safe? An Honest Read of the Phase 2 Data
• What Does Retatrutide Do? A Direct Look at the Phase 2 Numbers
• Does Retatrutide Cause Hair Loss? A Look at the Phase 2 Data and the Mechanism
• Tool: dosage calculator

Sources

1. Jastreboff AM, Kaplan LM, Frias JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity (A Phase 2 Trial). New England Journal of Medicine. 2023.
2. Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide in Type 2 Diabetes: A Phase 2 Trial. The Lancet. 2023.
3. Sanyal AJ et al. Retatrutide for Metabolic Dysfunction-Associated Steatotic Liver Disease. Nature Medicine. 2024.
4. Eli Lilly Q4 2024 earnings disclosure: TRIUMPH program update.
5. ClinicalTrials.gov NCT05882045: A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Are Overweight (TRIUMPH-1).
6. ClinicalTrials.gov NCT05298254: Phase 2 dose-finding study of retatrutide for obesity.
7. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). NEJM. 2021.
8. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). NEJM. 2022.
9. FDA Drug Approvals Database (no retatrutide approval as of May 2026).
10. Endocrine Society Clinical Practice Guideline on Pharmacotherapy of Obesity. 2024 update.
11. American Diabetes Association Standards of Care 2025 (investigational therapies summary).
12. USP General Chapter 797 (Pharmaceutical Compounding - Sterile Preparations).

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform connecting patients to independent licensed providers and U.S.-based pharmacies. We do not sell, supply, prescribe, or dispense retatrutide. Retatrutide is investigational and not FDA-approved. This page is educational only.

Compounded Medication Notice. FormBlends works with state-licensed 503A compounding pharmacies for medications other than retatrutide. Compounded GLP-1 medications are not FDA-approved and have not been reviewed for safety, efficacy, or quality by the FDA. They are not interchangeable with branded drugs.

Results Disclaimer. The percentage weight loss figures cited come from the Jastreboff et al. phase 2 trial in adults with obesity over 48 weeks. Individual outcomes vary based on baseline weight, adherence, diet, exercise, and individual response. Trial averages should not be read as personal predictions.

Trademark Notice. Retatrutide is an investigational compound developed by Eli Lilly and Company. Wegovy and Ozempic are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly, Novo Nordisk, or any other company referenced.